[Inactivation by 4,6 disubstituted pyrazolo (3,4-d) pyrimidines of the arsenolysis of guanosine by erythrocyte purine nucleoside phosphorylase].
New drugs are proposed in an attempt to reduce the overformation of uric acid in man. The procedure is based on the inhibition of human purine nucleoside phosphorylase selectively investigated in its phosphorolytic sequence. But for technical reasons, analogous inactivation of the enzyme in its comparative guanosine arsenolysis is subject to experimentation.
D000818:Animals; D001149:Arsenates / Q000378:metabolism; D004912:Erythrocytes / Q000201:enzymology*; D006151:Guanosine / Q000378:metabolism; D006801:Humans; D051379:Mice; D010117:Oxypurinol / Q000031:analogs & derivatives; D010430:Pentosyltransferases / Q000037:antagonists & inhibitors*; D011683:Purine-Nucleoside Phosphorylase / Q000037:antagonists & inhibitors* / Q000097:blood; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D013329:Structure-Activity Relationship; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors
D001149:Arsenates; D011743:Pyrimidines; D006151:Guanosine; D014969:Xanthine Oxidase; D010430:Pentosyltransferases; D011683:Purine-Nucleoside Phosphorylase; D010117:Oxypurinol
Inactivation, par des pyrazolo [3,4-d] pyrimidines 4,6 disubstituées, de l'arsénolyse de la guanosine par la purine nucléoside phosphorylase érythrocytaire